Sandoz Canada Aims For 10 Biosimilar Launches In Next Decade
Pegfilgrastim And Rituximab Biosimilars Coming Soon
Speaking with Generics Bulletin as Sandoz Canada unveiled its landmark public education campaign, The Biosimilars Generation, Karine Matteau, the company’s biosimilars leader, talked about how it plans to remain a leader in the biosimilars field as well as the company’s response to the COVID-19 pandemic.
You may also be interested in...
Merck, Sharp & Dohme’s Brenzys biosimilar version of Amgen’s Enbrel has received four new indications in Canada, bringing it in line with Sandoz’ rival biosimilar, Erelzi.
Sandoz has failed to overturn on appeal an invalidity ruling for two patents covering Enbrel in the US, barring a path to market for its Erelzi biosimilar, potentially until patent expiry in 2029.
A dedicated website will spearhead a public education campaign initiated by Sandoz Canada for biosimilars, as their influence and presence continue to grow in the North American market. Sandoz itself is planning a portfolio of five products by the middle of 2021.